Low-certainty evidence suggests that off-label fluoxetine may decrease weight compared with placebo .
However , low-certainty evidence suggests an increase in the risk for dizziness , drowsiness , fatigue , insomnia and nausea following fluoxetine treatment
BACKGROUND Fluoxetine is a serotonin reuptake inhibitor indicated for major depression .
It is also thought to affect weight control : this seems to happen through appetite changes result ing in decreased food intake and normalisation of unusual eating behaviours .
However , the benefit-risk ratio of this off-label medication is unclear .
OBJECTIVES To assess the effects of fluoxetine for overweight or obese adults .
[Effectiveness of serotonergic agonists in the treatment of obese patients].
OBJECTIVE To compare the effectiveness of two interventions in the treatment of obese patients :  hypocaloric diet and hypocaloric diet plus serotoninergic medication . DESIGN R and omised clinical trial . SETTING Primary Care . Out-patient Endocrinology clinic . PATIENTS The trial included 60 obese adults , assigned at r and om to two groups of 30 each . Both groups were comparable for sex , age , weight and Body Mass Index . Weight controls were performed at 2 , 4 and 6 months . RESULTS There were no significant differences in weight losses at the times studied ( 2 , 4 and 6 months ) between the Control ( Hypocaloric diet ) and Study ( Hypocaloric diet plus medication ) groups . There were significant weight losses in both groups analysed between 2 and 4 months , with a Body Mass Index which went down from 36.2 to 34.12 and from 35.52 to 33.57 ( p < 0.001 ) in the Control and Study groups , respectively . CONCLUSIONS No significant differences were observed in the results obtained for obese patients between a hypocaloric diet supplemented by serotoninergic medication and a hypocaloric diet
Low-certainty evidence suggests that off-label fluoxetine may decrease weight compared with placebo .
However , low-certainty evidence suggests an increase in the risk for dizziness , drowsiness , fatigue , insomnia and nausea following fluoxetine treatment
BACKGROUND Fluoxetine is a serotonin reuptake inhibitor indicated for major depression .
It is also thought to affect weight control : this seems to happen through appetite changes result ing in decreased food intake and normalisation of unusual eating behaviours .
However , the benefit-risk ratio of this off-label medication is unclear .
OBJECTIVES To assess the effects of fluoxetine for overweight or obese adults .